



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/487,318 01/19/00 REID

L 113918.101

021269
PEPPER HAMILTON
600 FOURTEENTH STREET NW
WASHINGTON DC 20005

HM22/0705

EXAMINER

NGUYEN, Q

ART UNIT

PAPER NUMBER

1632

DATE MAILED:

07/05/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

09/487,318

Applicant(s)

REID ET AL.

Examiner

Quang Nguyen

Art Unit

1632

-- Th MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 16 April 2001.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-9, 11-35, 38, 39 and 42-46 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-9, 11-35, 38, 39 and 42-46 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 10.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

DETAILED ACTION

Applicants' amendment filed on April 16 in Paper No. 9 has been entered. Claims 1-9, 11-35, 38-39 and 42-46 are pending in the present application.

The text of those sections of Title 35 U.S.C. Code not included in this action can be found in a prior office action.

Response to Amendment

The rejection of claims 1-8 under 35 USC 102(b) as being anticipated by Muench et al. (Blood 83:3170-3181, 1994) or Muench et al. (Blood 89:1364-1375, 1997) is withdrawn in light of Applicants' amendment.

The rejection of claims 1-9 and 16-17 under 35 USC 102(b) as being anticipated by Craig et al. (J. Exp. Med. 177:1331-1342, 1993) is withdrawn in light of Applicants' amendment.

With respect to the pending method claims that are subjected to outstanding prior art rejections, Examiner would like to suggest Applicants to recite a more specific selecting step (c) for selecting immature cells exhibiting one or more markers indicative of expression of alpha-fetoprotein, albumin or both to distinguish the present invention from the prior art. For example, intracellular staining of cells with antibodies specific for alpha-fetoprotein and the stained cells are sorted by flow cytometry. This would obviate the outstanding prior art rejections.

New Matter

Newly added claim 45 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 45 recites "the method of claim 3 in which the immature cells have a diameter greater than about 5 microns", There is literal no support in the originally filed specification for retaining immature cells have a diameter greater than about 5 microns. The specification teaches the use of hepatic progenitors of 7-15 microns for the instant invention (page 13, line 25). Therefore, given the lack of guidance provided by the originally filed specification, it would appear that Applicants did not have possession of the claimed invention at the time the application was filed.

Claim Rejections - 35 USC § 112

Claims 27-35 and 39 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention for the same reasons set forth in the previous Office Action mailed on 11/14/200 in Paper No. 7 (pages 6-8).

Claims 27-34 are directed to a method of treating liver dysfunction or disease responsive to treatment with liver progenitors in a subject in need thereof, comprising administering to the subject an effective amount of human liver progenitors, their

Art Unit: 1632

progeny, more mature forms thereof, or combinations thereof, in a pharmaceutically acceptable carrier and treating the liver dysfunction or disease.

Claim 35 is directed to a method of treating a disease in a subject in need thereof comprising administering an effective amount of human hepatic progenitors, their progeny, or more mature forms thereof in which the human hepatic progenitors, their progeny, or more mature forms harbor exogenous nucleic acid.

Claim 39 is drawn to a pharmaceutical composition comprising an enriched population of human liver progenitors, their progeny, or more mature forms thereof, which human liver progenitors exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both; and a pharmaceutically acceptable carrier.

The specification teaches by exemplification the isolation of human liver progenitor cells from fetal and adult human livers. With regard to the nature of the instant claims, example 10 of the specification discloses that upon injection of hepatic progenitors infected with recombinant adenovirus expressing human urokinase plasminogen activator (uPA), into the portal vein of C57BL/6 female mice, hepatic damage and high rates of 3H-thymidine uptake were observed. Transient elevation of serum urokinase reached a peak value at day 4, then fell back to a background level on day 12, while hepatic 3H-thymidine uptake began on day 3 and persisted for 8 days. Although initial moderate inflammatory infiltrate comprising macrophages and neutrophils was noted, by three to four weeks the infiltrate was resolved and the liver appears normal. It was suggested that the urokinase expression in combination with hepatic progenitors induced significant liver parenchymal cell regeneration. The above

Art Unit: 1632

evidence has been noted and considered. However, it can not be reasonably extrapolated to the instant claimed invention.

The specification is not enabled for the instant claimed invention because it fails to provide sufficient teachings and guidance demonstrating that by administering human liver progenitors of the present application into a subject having liver dysfunction or disease, the subject would be treated for symptoms associated with the liver dysfunction or disease. There is no apparent correlation between an increase in the uptake of hepatic 3H-thymidine in mice treated with hepatic progenitors infected with recombinant adenovirus expressing human urokinase plasminogen activator (uPA) in example 10 to obtaining any therapeutic effects for treatment method claims. Thus, there is a lack of a nexus between a specific given example provided by the specification and the instant methods of treatment. Nor does the prior art teach such a correlation. In addition, the specification fails to provide specific relevant information such as the effective cell dosages, the frequency of administration and the exact site of introduction for a given specific liver dysfunction or disease to obtain any therapeutic effects for the claimed treatment methods. Moreover, there is no evidence indicating that the newly introduced human liver progenitors are properly engrafted, proliferated, and differentiated into mature and functional liver cells in any treated subject. The mere mentioning of advantages offered by human liver progenitors for *ex vivo* gene therapy and routes of transplantation (See specification, pages 40-44) is not seen as providing enablement as there is no correlation between these and a therapeutic outcome. Without the specific teaching or guidance provided by the specification, it would have

Art Unit: 1632

required undue experimentation for one skilled in the art to use the instant claimed invention. The CAFC has stated that "patent protection is granted in return for an enabling disclosure, not for vague intimations of general ideas that may or may be workable". The court continues to state that "tossing out the mere germ of an idea does not constitute an enabling disclosure" and that "the specification, not knowledge in the art, that must supply the novel aspects of an invention in order to constitute adequate enablement". (See *Genetech, Inc. v. Novo Nordisk A/S*, 42 USPQ 2d 1001, at 1005).

With regard to the breadth of claim 35 encompassing human hepatic progenitors, their progeny, or more mature forms thereof comprising any and all exogenous nucleic acid to treat a disease in a subject, the specification fails to teach any specific vector used to deliver and express a specific gene (a therapeutic protein) in human hepatic progenitor cell populations of the instant claimed invention for treating a specific disease. At the effective filing date of the present application, it has been noted that sub-optimal vectors and the lack of long-term and stable transgene expression are some of the factors limiting an effective gene therapy. In a review on gene delivery systems available for gene therapy (Methods of gene delivery, Hematol. Oncol. Clin. North Am. 12:483-501, 1998), Wivel and Wilson stated that "One of the major challenges still confronting the field is the design of more efficient vectors. The gene delivery systems being used today will undoubtedly be seen as crude when compared with future developments. It is unlikely that there will ever be a universal vector, but rather there will be multiple vectors specifically designed for certain organ sites and certain diseases...It will be necessary to do much more fundamental research in cell

Art Unit: 1632

biology, virology, immunology, and pathophysiology before vectors can be significantly improved.” (pages 498–499 in Summary section). Additionally, factors such as the level of mRNA produced, the stability of the protein produced, the protein’s compartmentalization within the cell or its secretory fate differ dramatically based on which protein being produced, and therefore the desirable therapeutic effect sought to achieve. Thus, the level of gene expression, its duration, and its *in vivo* therapeutic effects are not always predictable, and they can not be overcome with routine experimentation.

For clarification on the rejection of claim 39 directed to a pharmaceutical composition comprising an enriched population of human liver progenitors, their progeny or more mature forms thereof, the instant specification is not enabled for the use of said composition to treat liver dysfunction or disease for the same reasons discussed above. It is noted that enablement requires the specification to teach how to make and use the claimed invention.

Accordingly, due to the lack of direction, guidance presented in the specification regarding to the administration of human liver progenitors, their progeny, more mature forms thereof to treat liver dysfunction or disease in a subject, the absence of working examples, and the breadth of the claims, it would have required undue experimentation for one skilled in the art to make/use the claimed invention.

Response to Arguments

Applicants' arguments related to the above rejection in the Amendment filed on April 16, 2001 in Paper No. 9 (pages 4-6) have been fully considered.

Applicants basically argued that the instant specification provides sufficient guidance for the use of the isolated progenitors of the invention and their progeny for the treatment of liver diseases and dysfunctions as claimed by referring to various passages in the application. Applicants maintained that the administration of suspensions of hepatocytes to subjects is routine, and that Applicants discussed the advantages hepatic progenitors versus hepatocytes with regard to cell size, immunological rejection and proliferative capacity for treatment purposes. Applicants also maintained that "Once the hepatic progenitors are administered they then go about the business of alleviating the medical condition affecting the liver". Additionally, Applicants cited the case *Hybritech vs. Monoclonal Antibodies, Inc.* to point out that the level of precision need only be as precise as the art can offer. Applicants further cited the reference of Halibullah reporting the use of hepatocytes for treatment of fulminant liver failure by simple injection into the peritoneum to establish the general validity and ease of cell therapy with liver-derived cells. Examiner respectfully finds Applicants' arguments to be unpersuasive for the following reasons.

The mere general description or mentioning the advantages offered by human liver progenitors for treating a host of liver dysfunction, disorders and diseases such as hepatocholangitis, cirrhosis, hepatitis, acute and chronic liver failure, hepatocarcinoma,

Art Unit: 1632

hepatoblastoma and others, is not seen as providing enablement as there is no correlation between these general descriptions and contemplated therapeutic outcomes. Without the specific guidance provided by the specification, it would have required undue experimentation for one skilled in the art to make and use the methods as claimed. It should be noted that the physiological art is recognized as unpredictable (MPEP 2164.03), especially for achieving therapeutic effects for a whole host of liver diseases and disorders as claimed. In this regard, the cited case law of Hybridtech vs. Monoclonal Antibodies, Inc. concerning antibodies affinities is not applicable. In contrary to Applicants' simple assertion that once the hepatic progenitors are administered into a subject suffering from a liver dysfunction or disease, they then go about the business of alleviating the medical condition affecting the liver, there are several issues that the specification fails to address such that contemplated therapeutic outcomes could be attained. As noted in the previous Office Action, there is no evidence indicating that the introduced human liver progenitors are properly engrafted, proliferated, and differentiated into mature and functional liver cells in any treated subject to yield any therapeutic outcomes or effects. As recited, the claims encompass syngeneic, allogeneic and xenogenic transplantation of human liver progenitors into a subject in need of treatment. There is no evidence indicating that that the delivered human liver progenitors, their progeny or mature forms thereof would be free from the adverse host immune reactions. It is already well known in the art that adverse host immune rejection reactions present a formidable challenge in the transplantation of allogeneic and particularly xenogeneic cells and tissues. Even in the exemplified

Art Unit: 1632

example, moderate inflammatory responses were noted and persisted for 3 to 4 weeks in the mouse model, and there is no evidence indicating that the administered liver progenitors proliferate, differentiate into functional liver cells. The instant claims also encompass any and all administering sites for the delivery of liver progenitors into a subject having a liver dysfunction or disease. However, it is unclear whether effective levels of liver progenitors can home in to a diseased or disordered liver to proliferate and differentiate into functional mature cells to yield therapeutic effects by any and all routes of administration. Moreover, Dabeva et al. (Am. J. Pathology 156:2017-2031, 2000; IDS) have stated that "Several studies also report successful engraftment and differentiation of early fetal liver tissue or cell suspensions after transplantation into ectopic sites. However, engrafted liver tissue masses at ectopic sites do not expand very much, and it is unlikely that such limited liver transplantation will have broad therapeutic application" (page 2029, column 2, last 3 sentences continue to lines 1-4 of column 1, page 2030). With regard to the reference of Habibullah et al. (Transplantation 58:951-977, 1994, IDS), as rightly pointed out by Applicants that the treatment with hepatocyte in the study of Habibullah et al. is not the same as treatment with liver progenitors, for one thing the starting material is not the same. Therefore, the positive therapeutic effects observed from the study of Habibullah et al. could not be reasonably extrapolated to the contemplated therapeutic effects to be achieved by the instant invention. Furthermore, it should be noted in the study of Habibullah et al. the beneficial effects were limited specifically to 2 patients having PSE of grade III and 1 patient having PSE of grade IVa, and that the selected patients have fulminant hepatic

Art Unit: 1632

failure (FHF) of less than two weeks of duration. Additionally, it is unclear about the fate of the transplanted fetal hepatocytes. Whether they could be stably engrafted in the peritoneum, continued to proliferate and provided beneficial effects for the patients. Habibullah et al. also noted that in rat and rabbit models of fulminant hepatic failure, peritoneal survival of transplanted syngeneic hepatocytes lasted only about 10 days (page 352, column 1, full paragraph, lines 3-6). Because of the very limited beneficial effects observed, specifically for 3 patients with PSE of grade III and IVa in a very small selected patient population (7 patients having FHF less than two weeks of duration), the results of Habibullah et al. certainly can not be reasonably extrapolated to the therapeutic results hoped to be achieved for treating any and all liver dysfunction and diseases in a subject as encompassed by the breadth of the instant claims. Lastly, in a recent review on liver stem cell, Shafritz (Hepatology, pages 1399-1400, 2000; IDS) stated that "...liver transplantation is the only available current therapy for end-stage liver failure.....finding alternative methods for liver replacement is of utmost importance. One such method would be functional repopulation of the diseased liver by cell transplantation." (page 1399, column 1, lines 1-6). So clearly, a method for treating any and all liver dysfunction in a mammal using cell transplantation, including human liver progenitors of the instant invention, is not achievable or routine or predictable even in the year 2000, let alone at the effective filing date of the present application (January 19, 1999). Interestingly, Shafritz et al. further noted that "the clonality and bipotent nature of isolated liver stem/progenitor cells need to be confirmed by *in vivo* transplantation studies" because there is no consistent data in the art (page 1400, col.

Art Unit: 1632

1, middle paragraph, lines 12-26). Accordingly, given the lack of provided by the instant specification, the unpredictability of the physiological art, the state of liver progenitor cell transplantation, and the breadth of the instant claims, it would therefore have required undue experimentation for a skilled artisan to make and use the methods as claimed.

With regard to claim 35, Applicants argued that the specification provides sufficient guidance regarding to providing hepatic precursors with an exogenous gene of interest for treatment purposes by citing various passages in the specification and example 10. Applicants further argued that it is not necessary to give an example of every species. Although Examiner agrees with Applicants the latter point, however, Applicants' arguments are found to be unpersuasive. This is again because the general description in the specification is not deemed to be equivalent to the therapeutic outcomes contemplated by the method as claimed. Furthermore, the specification is not enabled for the claimed method for the reasons stated in the preceding paragraphs. Additionally, there are issues such as whether the genetically modified human hepatic progenitors, their progeny or mature forms thereof could be stably engrafted, differentiated and proliferated into functional liver cells could be achieved in the treated subject and whether said cells persist in a treated subject for a sufficient period of time to provide a stable, long-term *in vivo* expression of therapeutic transgenes to yield therapeutic outcomes for any and all diseases. The nature of the claim 35 falls within the realm of *ex vivo* gene therapy which was highly unpredictable at the effective filing date of the present application with respect to achieving therapeutic results. As noted in the previous Office Action, factors such as sub-optimal vectors, the lack of a long-term

Art Unit: 1632

and stable *in vivo* transgene expression are some of the factors limiting the effectiveness of *ex vivo* gene therapy. For examples, Palmer et al. (Proc. Natl. Acad. Sci. 88:1330-1334, 1991) demonstrated that the *in vivo* expression of human factor IX by transplanted syngeneic recombinant fibroblasts was transient and vanished 1-5 weeks post-transplantation. Riddell et al. (Nature Med. 2:216-223, 1996) reported that five out of six patients seropositive for human immunodeficiency virus quickly developed cytotoxic T-lymphocytes responses specific to a novel protein and eliminated infused autologous CD8+ HIV-specific cytotoxic T cells transduced with a fusion suicide gene (See abstract). Given the unpredictability of the gene therapy art coupled with the lack of specific guidance provided by the instant specification with respect to attaining therapeutic effects for any and all disease in a host by overcoming the aforementioned factors, it would have required undue experimentation without a predictable expectation of success for one skilled artisan to make and use the instant claimed invention.

Accordingly, claims 27-35 and 39 are rejected under 35 U.S.C. 112, first paragraph for the reasons of record.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-2, 4-9, 11 and amended claims 12-20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for the same

Art Unit: 1632

reasons set forth in the previous Office Action mailed on 11/14/200 in Paper No. 7 (page 9).

The terms "substantially", "relatively large size" and "relatively small size" in claim 1 are relative terms that render the claim indefinite. The terms "substantially", "relatively large size" and "relatively small size" are not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Clarification is requested. It is noted that the amended claim 12 also contains the term "substantially".

Response to Arguments

Applicants' arguments related to the above rejection in the Amendment filed on April 16, 2001 in Paper No. 9 (pages 6-7) have been fully considered.

Applicants argued that the meaning of "relatively large size" and "relatively small size" is well established in the disclosure of the invention and will be clear to one skilled in the art upon examination of the specification by referring to page 26, line 30 and page 27, line 12 as examples. Examiner respectfully finds Applicants' argument to be unpersuasive because the terms are not clearly defined in the specification and therefore the metes and bounds of the claims are still not exactly determined. If Applicants intend to remove cells larger than 15 microns in diameter while retaining cells less than 15 microns in the claimed method, then please recite the claims as such. Although Applicants removed the term "substantially single" in amended claim 1 as

suggested by Examiner, the same term is still present in the amended independent claim 12.

Claim Rejections - 35 USC § 102

Claims 12-19 are rejected under 35 U.S.C. 102(b) as being anticipated by Muench et al. (Blood 83:3170-3181, 1994) or Muench et al. (Blood 89:1364-1375, 1997) for the same reasons set forth in the previous Office Action mailed on 11/14/200 in Paper No. 7 (pages 11-12).

The claims are drawn to a method of providing a composition comprising an enriched population of human liver progenitors comprising: (a) providing a substantially single cell suspension of human liver tissue, and (b) subjecting the suspension to a positive or negative immunoselection, such that a mixture of cells is provided, which mixture of cells is comprised of an enriched population of human liver progenitors, which human liver progenitors themselves, their progeny, or more mature forms thereof exhibit one or more markers indicative of expression of alpha-fetoprotein. Claim 20 is directed to a human liver progenitor isolated by the same method.

Muench et al. (1994, 1997) disclosed a method for the isolation of human fetal liver progenitors and hematopoietic stem cells derived from human fetal liver. The method comprises subjecting a suspension of fetal liver cells to a density centrifugation to obtain light density fetal liver (LDFL) cells (See column 1, page 3171, Muench et al., 1994; column 2, first paragraph, page 1365, Muench et al., 1997). LDFL cells were depleted of glycophorin A (GPA⁺) cells by immunomagnetic beads depletion (a form of

Art Unit: 1632

negative immunoselection), then GPA⁻ LDFL cells were enriched for CD34⁺ cells by panning using an anti-CD34 antibody-coated tissue culture flasks. GPA⁻ LDFL cells were also fractionated based on cell-surface antigen expression by FACS (See column 1, page 3171, Muench et al., 1994; column 2, first paragraph, page 1365, Muench et al., 1997). As the method of Muench et al. (1994, 1997) and the method claimed can not be distinguished, the method of Muench et al. inherently produces an enriched population of human liver progenitor cells as claimed. Therefore, the references anticipate the claimed invention.

Claims 21-23 and 42-44 are rejected under 35 U.S.C. 102(b) as being anticipated by Muench et al. (Blood 83:3170-3181, 1994) or Muench et al. (Blood 89:1364-1375, 1997) for the same reasons set forth in the previous Office Action mailed on 11/14/200 in Paper No. 7 (pages 12-13).

Claims 21-23 are drawn to a composition comprising an enriched population of human liver progenitors, their progeny, or more mature forms thereof, which human liver progenitors exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both; the same composition wherein the progenitors comprise hepatic progenitors, hematopoietic progenitors, mesenchymal progenitors, or combinations thereof, and the same wherein said human liver progenitors, their progeny, or more mature forms thereof express CD14, CD34, CD38, CD117, ICAM or combinations thereof. Claim 42 is directed to isolated human liver progenitors, their progeny or more mature forms thereof which exhibit one or more markers indicative of expression of

Art Unit: 1632

alpha-fetoprotein, albumin, or both. Claims 43-44 are drawn to isolated human liver progenitors, their progeny or more mature forms thereof which exhibit the phenotype glycophorin A⁻, CD45⁻, alpha-fetoprotein⁺⁺⁺, albumin⁺, and ICAM⁺, and the same which further express CD14⁺, CD34⁺⁺, CD38⁺⁺, CD117⁺⁺⁺, or combinations thereof.

Muench et al. (1994) disclosed the isolation of human fetal liver progenitors with a high proliferative potential and a phenotype of CD34⁺, CD33⁺, CD13⁺, CD38⁻, lin⁻ (lineage= CD3, CD8, CD10, CD14, CD15, CD16, CD19, CD20 and glycophorin A), CD45RA⁻, CD45RO⁻, CD71⁻, and heterogeneous *for c-kit* or CD117 (See abstract and page 3171). Muench et al. (1997) disclosed the isolation of hematopoietic stem cells derived from human fetal liver, with a phenotype of CD4⁺, CD34⁺⁺, Lin⁻, CD117⁺, CD38⁻, CD45RA⁻ (See abstract and page 1365). As the method of Muench et al. (1994, 1997) and the method claimed can not be distinguished, the method of Muench et al. inherently produces an enriched population of human liver progenitor cells as claimed. Therefore, the references anticipate the claimed invention.

Claims 12-15, 18-23, and 42-44 are rejected under 35 U.S.C. 102(b) as being anticipated by Craig et al. (J. Exp. Med. 17:1331-1342, 1993) for the same reasons set forth in the previous Office Action mailed on 11/14/200 in Paper No. 7 (pages 13-14).

Craig et al. disclosed the isolation of human hematopoietic progenitor cells derived from human fetal liver with a phenotype of Thy-1⁺, CD34⁺, CD38^{low}, CD45RA⁻, CD45RO⁺, CD71^{low}, and CD117^{low} (See abstract, and column 1, second paragraph, page 1332). The method comprises the preparation of low density mononuclear cells

by density centrifugation using Ficoll-Paque (column 1, page 1332, lines 24-26). In some samples, red blood cells were lysed by the addition of 10-fold excess of ammonium chloride lysing solution (column 1, page 1332, lines 30-32). Subpopulations of low density mononuclear cells were subsequently sorted by multiparameter flow cytometry, a form of positive immunoselection (column 2, page 1335, second paragraph). As the method of Craig et al. (1993) and the method claimed can not be distinguished, the method of Craig et al. inherently produces an enriched population of human liver progenitor cells as claimed. Thus, the reference anticipates the claimed invention.

Claims 11, 20, 21-26 and 42-44 rejected under 35 U.S.C. 102(e) as being anticipated by Faris (U.S. Patent No. 6,129,911 with an effective filing date of 7/10/1998) for the same reasons set forth in the previous Office Action mailed on 11/14/200 in Paper No. 7 (pages 14-15).

Claims 21-26 are drawn to a composition comprising an enriched population of human liver progenitors, their progeny, or more mature forms thereof, which human liver progenitors exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both; the same composition in which progenitors harbor exogenous nucleic acid promoting the expression of at least one polypeptide of interest. Claims 11 and 20 are directed to a human liver progenitor isolated by the methods of claims 1 and 14, respectively. Claims 41-43 are drawn to isolated human liver progenitors encompassing hepatic progenitors.

Faris taught the preparation and isolation of a liver cell cluster of less than 10 cells comprising a liver stem cell and a hepatocyte, and a primary liver stem cell derived from human liver tissue, in which said stem cell comprises DNA encoding a heterologous polypeptide, such as ornithine transcarbamylase, glutamine synthetase, Factor XIII, Factor IX and others (See columns 1-3, and the claims). The primary liver stem cell derived from human liver tissue is defined as undifferentiated cell that differentiates into a mature functional hepatocyte or bile duct cell (column 1, lines 37-39) which is consistent with the definition of hepatic progenitors of the instant claimed invention (cells give rise to hepatocytes and biliary cells, page 22, lines 3-4). Since a product and its properties can not be separated, the composition of isolated liver cell cluster of Faris is the same as an enriched population of human liver progenitors, their progeny or more mature forms thereof, or isolated human liver progenitors of the same instant invention, regardless how they are isolated, the reference therefore anticipates the claimed invention.

Claim Rejections - 35 USC § 103

Claims 1-6, 8, 12-19 and newly added claims 45-46 are rejected under 35 U.S.C. 103(a) as being unpatentable over Reid et al. (U.S. Patent No. 6,069,005) for the same reasons set forth in the previous Office Action mailed on 11/14/200 in Paper No. 7 (pages 16-17).

Reid et al. disclosed a method of isolating hepatic progenitors from rat fetal livers utilizing panning techniques and flow cytometry on single cell suspension of liver cells

Art Unit: 1632

(See claim 1, column 20). The method comprises the panning and fluorescence activated cell sorting of fetal liver cells using specific antibodies to remove mature hepatocytes, mature bile duct cells, endothelial cells, mesenchymal cells and hemapoietic cells for obtaining a cell population enriched for immature hepatic cell types which were subsequently separated into distinct subcategories by multiparametric fluorescence activated cell sorting (See Examples I and II). The panning stage involves multiple steps (see Table 3 in col. 6, for example) resulting in isolated cells enriched up to 5-fold for AFP mRNA and 2-fold for albumin mRNA (col. 17, lines 19-27). One of the panning steps is a selecting step for cells exhibiting one or more markers indicative of expression of alpha-protein, albumin or both, for this instance mRNAs of AFP and albumin. Since a product and its properties can not be separated, hepatic progenitors isolated by the disclosed method also possess markers indicative of expression of alpha-fetoprotein, albumin, or both (full-length mRNAs, for examples), as well as alpha-fetoprotein-like immunoreactivity, albumin-like immunoreactivity, or a combination thereof as evidenced by the enrichment of AFP mRNA and albumin mRNA in selected cells after the panning. It is further noted that fetal liver cells selected for flow cytometry in the disclosed method have a broad range in cell size, 5 to 15 microns (See column 17, lines 50-51). Although Reid et al. did not specifically teach a method of providing a composition comprising a mixture of cells derived from human liver tissue or an enriched population of human liver progenitors, Reid et al. stated that their method offers a systematic approach to isolating hepatoblasts (hepatic progenitors) from any age from any species (column 2, lines 45-49).

Accordingly, it would have been obvious to a person of ordinary skill in the art at the time of invention was made to modify the method disclosed by Reid et al. by replacing rat fetal liver tissue as the starting material with human liver tissues. The motivation for one carry out the above modification is to obtain a composition enriched in a population of human liver progenitors for cellular characterization as well as for cell transplantation studies. Thus, the claimed invention as a whole was *prima facie* obvious in the absence of evidence to the contrary.

Claims 21, 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Muench et al. (Blood 83:3170-3181, 1994) or Muench et al. (Blood 89:1364-1375, 1997) in view of Reid et al. (U.S. Patent No. 5,789,246, PTO-1449 AB) for the same reasons set forth in the previous Office Action mailed on 11/14/200 in Paper No. 7 (pages 17-18).

The claims are drawn to a composition comprising an enriched population of human liver progenitors, their progeny, or more mature forms thereof, which human liver progenitors exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin, or both; and a cell culture comprising the same composition, an extracellular matrix component, and a culture medium (Claim 38).

Muench et al. (1994) disclosed the isolation of human fetal liver progenitors with a high proliferative potential and a phenotype of CD34⁺, CD33⁺, CD13⁺, CD38⁻, lin⁻ (lineage= CD3, CD8, CD10, CD14, CD15, CD16, CD19, CD20 and glycophorin A), CD45RA⁻, CD45RO⁻, CD71⁻, and heterogeneous for *c-kit* or CD117 (See abstract and

Art Unit: 1632

page 3171). Muench et al. (1997) disclosed the isolation of hematopoietic stem cells derived from human fetal liver, with a phenotype of CD4⁺, CD34⁺⁺, Lin⁻, CD117⁺, CD38⁻, CD45RA⁻ (See abstract and page 1365). Since a product and its properties can not be separated, human fetal liver progenitors and human hematopoietic stem cells derived from human fetal liver isolated by Muenche et al. (1994, 1997) also possess the same properties as those of the enriched population of human liver progenitor cells in the instant claimed invention. However, Muench et al. (1994, 1997) did not teach a cell culture comprising these cell populations, an extracellular matrix component, and a culture medium. However, Reid et al. taught a cell culture comprising hepatocyte precursors being plated on or in a matrix of collagen type IV and in the serum-free, hormonally defined medium (See columns 2-4) for the expansion or proliferation of hepatocyte precursors.

Accordingly, it would have been obvious to a person of ordinary skill in the art at the time of invention was made to adopt the cell culture system taught by Reid et al. for the expansion of human fetal liver progenitors and hematopoietic stem cells derived from human fetal liver disclosed by Muench et al. (1994, 1997). One would have been motivated to carry out the above modification for expanding human fetal liver progenitors and hematopoietic stem cells for uses in artificial livers, for toxicology and pharmacology studies (See abstract in Reid et al.). Thus, the claimed invention as a whole was *prima facie* obvious in the absence of evidence to the contrary.

Response to Arguments

Applicants' arguments related to the above rejections in the Amendment filed on April 16, 2001 in Paper No. 9 (pages 8-10) have been fully considered.

Applicants argued with respect to amended claims, none of the cited references disclose elements of the invention. Specifically, none of the cited references teach an enriched population which exhibit one or more markers indicative of expression of alpha-fetoprotein, albumin or both. As an example, Applicants argued that Muench et al. do not assess the expression of either alpha-fetoprotein or albumin or the correlation of expression of either protein with any marker described in Muench et al. (1994, 1997). Applicants further assert that there is no indication that the cells that Muench et al. identify inherently express either alpha-fetoprotein or albumin. Examiner respectfully finds Applicants' arguments to be unpersuasive for the following reasons. Although Examiner agrees with Applicants that the articles of Muench et al., Craig et al. and Faris do not assess the expression of either alpha-fetal protein or albumin in their cell preparations, however their cell preparations are enriched in CD34 (a common marker for progenitor or stem cells) cells, and such CD34 cells derived from human liver are known to express at least alpha-fetal protein as evidenced by the disclosure of the instant specification (page 32, Table 2; page 34, Table 3, for examples). It should be further noted that Munch et al. selected all CD34 cells derived from human fetal liver via panning using an anti-CD34 antibody. With respect to the cited reference of Reid et al., they specifically teach that the isolated hepatic progenitors after panning are enriched in AFP mRNA and albumin mRNA as noted above. Therefore, the cited references

Art Unit: 1632

disclose elements of the present invention. Accordingly, the claims are rejected for the reasons of record.

The following is a new ground of rejection necessitated by Applicants' amendment.

Claim Rejections - 35 USC § 103

Claims 1 and 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Reid et al. (U.S. Patent No. 6,069,005) in view of Muench et al. (Blood 83:3170-3181, 1994).

The teachings of Reid et al. have been discussed above. Reid et al. do not disclose the separation according to cell size, buoyant density or a combination thereof in the debulking step for their preparations of hepatic progenitors. However, Muench et al. (1994) disclosed a method for the isolation of human fetal liver progenitors comprising subjecting a suspension of fetal liver cells to a density centrifugation to obtain light density fetal liver (LDLFL) cells in the initial stage of the isolation procedure (See column 1, page 3171, Muench et al., 1994).

Accordingly, it would have been obvious to a person of ordinary skill in the art at the time of invention was made to modify the method of Reid et al. by substituting a panning step with a density centrifugation step to remove the unwanted cells during the isolation of hepatic progenitors as taught by Muench et al. The instant claimed method

Art Unit: 1632

is an obvious variant of Reid et al. Thus, the claimed invention as a whole was *prima facie* obvious in the absence of evidence to the contrary.

Claims 1 and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Reid et al. (U.S. Patent No. 6,069,005) in view of Craig et al. (J. Exp. Med. 17:1331-1342, 1993).

The teachings of Reid et al. have been discussed above. Reid et al. do not disclose teach selective lysis of the mature cells in their isolation procedure. However, during the isolation of human hematopoietic stem cells from fetal liver, Craig et al. teach that red blood cells were lysed by the addition of 10-fold excess of ammonium chloride lysing solution (column 1, page 1332, lines 30-32).

Accordingly, it would have been obvious to a person of ordinary skill in the art at the time of invention was made to modify the method of Reid et al. by further incorporating a lysis step to remove mature red blood cells during the isolation of liver progenitors as taught by Craig et al. The instant claimed method is an obvious variant of Reid et al. Thus, the claimed invention as a whole was *prima facie* obvious in the absence of evidence to the contrary.

Conclusions

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP

Art Unit: 1632

§ 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Quang Nguyen, Ph.D., whose telephone number is (703) 308-8339.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's mentor, Dave Nguyen, may be reached at (703) 305-2024, or SPE, Karen Hauda, at (703) 305-6608.

Any inquiry of a general nature or relating to the status of this application should be directed to Patent Analyst, Patsy Zimmerman, whose telephone number is (703) 308-0009.

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1632.

Quang Nguyen, Ph.D.


DAVE T. NGUYEN
PRIMARY EXAMINER